Pulmonx to Present at the Bank of America Securities 2026 Health Care Conference
Rhea-AI Summary
Pulmonx (Nasdaq: LUNG) will present at the Bank of America Securities 2026 Health Care Conference in Las Vegas on Tuesday, May 12, 2026 at 8:15 AM PT / 11:15 AM ET. A live and archived webcast will be available in the Investors section of the company website.
Positive
- None.
Negative
- None.
News Market Reaction – LUNG
In the Apr 29 session, LUNG declined 2.44%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 15 | Earnings date notice | Neutral | -2.7% | Scheduled Q1 2026 results release and earnings call details. |
| Mar 04 | Earnings results | Positive | +11.8% | Reported 2025 results and 2026 guidance with revenue growth and margin detail. |
| Mar 04 | Debt financing | Positive | +11.8% | Closed new five-year credit facility up to $60M to refinance debt. |
| Feb 20 | Earnings date notice | Neutral | +6.0% | Announced timing and webcast details for Q4 and 2025 results. |
| Dec 03 | Inducement grants | Neutral | +13.2% | Granted 1,625,000 inducement equity awards to new executives under plan. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent Pulmonx headlines, including earnings, credit facility, and inducement grants, have frequently coincided with positive one-day price moves.
Over the past six months, Pulmonx issued several key updates, including 2025 results with $90.5M revenue and new 2026 guidance, a $60M credit facility, and large inducement equity grants in December 2025. Earnings and financing news on March 4, 2026 were followed by strong positive moves of 11.81%, while an April 15, 2026 earnings-date announcement saw a smaller -2.67% reaction. Today’s conference participation fits into a cadence of regular investor communications.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be presenting at the Bank of America Securities 2026 Health Care Conference in Las Vegas on Tuesday, May 12, 2026, at 8:15 AM PT / 11:15 AM ET.
A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTraXTM Platform, and StratX® Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.
Pulmonx®, AeriSeal®, Chartis®, StratX®, and Zephyr® are registered trademarks and LungTraXTM is a trademark of Pulmonx Corporation.
Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com
